Drugs / Bifidobacterium lactis B94
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03165253 Comparator | Jun 2011 → Jun 2012 | Helicobacter pylori infectious disease | Bulent Ecevit University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bifidobacterium lactis B94 | “The second group was treated with the standard triple therapy and Bifidobacterium lactis B94 (5 × 109 CFU/dose) plus inulin (900 mg) for 14 days, concurrently.” PMID 28656129 ↗ Jun 2017 |
| Modality | Other / unclassified | “The aim of the study is to evaluate the effects of the synbiotic Bifidobacterium animalis ssp. lactis B94 plus inulin addition” NCT03165253 ↗ |
| Route | Oral | “Bifidobacterium animalis oral product” NCT03165253 ↗ |